Annual Activity Report 2025

FINANCIAL STATEMENTS

Consolidated fi nancial statements – fi nancial year ended December 31, 2025

Consolidated statement of changes in equity

Revaluation of the net liability in respect of de fi ned- bene fi t obligations

Unrealized gains and losses on fi nancial instruments

Total equity attributable to owners of the parent

Consolidated premiums and reserves

Currency translation reserves

Non controlling interests Total equity

Number of shares Capital

Notes

(in millions of euros)

January 1, 2024 Net income for the period Other items of comprehensive income Comprehensive income Dividends paid Capital increase Other changes (1) DECEMBER 31, 2024 Net income for the period

264,152,778 132

1,478

(143)

58

23 1,550

387

1,937

633

633

78

712

8

13

(161)

36 (113)

(23)

(136)

633

13

(161)

36

521

55

576 (84) 297

– (84)

22 9,146,340

5

292 (12)

297

12

–

–

10

10

273,299,118 137

2,393

(118)

(103)

59 2,367

369

2,736

404

404

145

550

Other items of comprehensive income Comprehensive income Dividends paid Other changes (2)

8

52

223 (224)

52

(8)

44

404 (25) 204

52

223 (224)

456 (25) 207

138 (91) 105 521

594

(115)

1

1

312

DECEMBER 31, 2025 3,526 (1) At December 31, 2024, other changes of 10 million euros correspond to the deconsolidation of non-controlling interests in companies in Niger. (2) At December 31, 2025, other changes for 312 million euros correspond to the acquisition by Sano fi of a 15.6% stake in Orano Med Theranostics for 295 million euros and the loss of control of Nurlikum Mining for 16 million euros (see Note 1.1). 273,299,118 137 2,976 (64) 120 (164) 3,005

6

319

Orano - Annual Activity Report 2025